Inhibrx Biosciences Inc (INBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -76,124 | -58,475 | -37,978 | -20,093 | -51,400 |
| Depreciation Amortization | 11,208 | 10,800 | 6,329 | 1,800 | 6,661 |
| Accounts receivable | 117 | -482 | 194 | 199 | N/A |
| Accounts payable and accrued liabilities | 10,426 | 11,605 | 5,677 | 6,303 | N/A |
| Other Working Capital | 12,691 | 12,566 | 12,581 | 9,443 | 3,485 |
| Other Operating Activity | -6,286 | -8,593 | -5,500 | -5,040 | 9,175 |
| Operating Cash Flow | $-47,968 | $-32,579 | $-18,697 | $-7,388 | $-32,079 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,364 | -752 | -453 | -91 | -1,810 |
| Investing Cash Flow | $-1,364 | $-752 | $-453 | $-91 | $-1,810 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 46,813 | 26,833 | 16,875 | N/A | N/A |
| Debt Repayment | -5,458 | -3,583 | -3,583 | -3,583 | N/A |
| Common Stock Issued | 136,877 | 136,854 | 0 | 0 | N/A |
| Other Financing Activity | -11,776 | -10,644 | -50 | -50 | 43,326 |
| Financing Cash Flow | $166,456 | $149,460 | $13,242 | $-3,633 | $43,326 |
| Beginning Cash Position | 11,540 | 11,540 | 11,540 | 11,540 | 2,103 |
| End Cash Position | 128,664 | 127,669 | 5,632 | 428 | 11,540 |
| Net Cash Flow | $117,124 | $116,129 | $-5,908 | $-11,112 | $9,437 |
| Free Cash Flow | |||||
| Operating Cash Flow | -47,968 | -32,579 | -18,697 | -7,388 | -32,079 |
| Capital Expenditure | -1,364 | -752 | -453 | -91 | N/A |
| Free Cash Flow | -49,332 | -33,331 | -19,150 | -7,479 | -32,079 |